Skip to main content
. 2022 Sep 22;28(10):2145–2154. doi: 10.1038/s41591-022-01969-y

Fig. 3. Survival according to CAR T product after PSM.

Fig. 3

a, Propensity score reflects the probability of receiving tisa-cel or axi-cel conditional on an exhaustive list of 14 pre-infusion covariates. PSM is based on matching patients with similar propensity score. Comparability according to each covariate (for instance, disease stage depicted here) of the resulting two sub-cohorts of patients receiving one CAR T or the other is checked using SMDs (Extended Data Fig. 3). b, DOR according to CAR T product (axi-cel, n = 168, red line; tisa-cel, n = 138, blue line) (P = 0.11). c, DOR according to CAR T product and response quality (complete response (CR) versus partial response (PR); P = 0.30 and P = 0.90, respectively) (axi-cel and CR, n = 126, red line; tisa-cel and CR, n = 88, blue line; axi-cel and PR, n = 42, brown line; tisa-cel and PR, n = 50, green line). d, PFS according to CAR T product (P = 0.0003). e, OS according to CAR T product (P = 0.0072). P values were calculated using two-sided log-rank tests. No adjustment was made for multiple comparisons. Shaded areas correspond to the 95% confidence bands using the Hall–Wellner method. CL, confidence limit; NA, not assessable.